Lifileucel
- Generic Name
- Lifileucel
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2306267-74-1
- Unique Ingredient Identifier
- R0835E18NH
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Iovance Biotherapeutics, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06481592
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸UofL Health - Brown Cancer Center, Louisville, Kentucky, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients
Phase 1
Active, not recruiting
- Conditions
- Pathologic Stage IIIC Cutaneous Melanoma AJCC v8Stage IV MelanomaLocally Advanced MelanomaPathologic Stage IIIB Cutaneous Melanoma AJCC v8Pathologic Stage IIID Cutaneous Melanoma AJCC v8
- Interventions
- Drug: CyclophosphamideDrug: FludarabineBiological: LifileucelBiological: PembrolizumabProcedure: Therapeutic Conventional Surgery
- First Posted Date
- 2022-01-04
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Richard Wu
- Target Recruit Count
- 2
- Registration Number
- NCT05176470
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath